Cipla Introduces Tirzepatide Drug Yurpeak for Diabetes and Obesity Treatment in India
Cipla has launched Yurpeak (tirzepatide), a once-weekly injectable medication intended for adult patients dealing with obesity and type 2 diabetes. As the second brand of Lilly's tirzepatide to be offered in India, Yurpeak will be available with a prescription in a multi-dose KwikPen.
Cipla Limited announced the introduction of Yurpeak (tirzepatide), a once-weekly injectable treatment option for managing both obesity and type 2 diabetes mellitus (T2DM). These conditions represent two of the most significant health challenges currently facing the country.
About Yurpeak (Tirzepatide)
Cipla possesses the exclusive rights to distribute and promote Yurpeak, which is the second brand of Lilly's tirzepatide in India, following its approval by the Drugs Controller General of India (DCGI). Tirzepatide stands out as the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is indicated as an addition to diet and exercise for treating Type 2 diabetes and aiding in chronic weight management for obese adults (BMI >= 30) or overweight individuals (BMI >= 27) who also have at least one weight-related comorbidity.
Yurpeak will be offered via prescription in the KwikPen format, with six available strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. This variety of dosages allows for precise, convenient, and user-friendly administration for patients. Health tracking apps like Shotlee can help monitor treatment progress and adherence.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Executive Commentary
According to Achin Gupta, Global Chief Operating Officer at Cipla Limited, the launch of Yurpeak signifies a major advancement in addressing obesity and type 2 diabetes mellitus, two chronic conditions that significantly burden India. Cipla is leveraging its established expertise and dedication to scientific advancement in chronic diseases and respiratory care to enter this therapeutic area. The company aims to improve access to advanced, globally recognized treatments through collaborations with companies like Lilly, combining innovation, purpose, and scale to ensure patients receive cutting-edge care wherever they are.
Expanding Access Across India
The availability of Yurpeak in India is expected to broaden access to tirzepatide, enabling more patients to experience the benefits of this innovative treatment. Cipla's main goal is to ensure Yurpeak's availability throughout India, including areas beyond major metropolitan centers. This will be achieved by utilizing its robust distribution network and in-depth understanding of the market to increase nationwide reach and accessibility.
Lilly will be responsible for manufacturing and supplying Yurpeak to Cipla, and its price will be consistent with that of Mounjaro.
Patient Education and Support
To support the introduction of Yurpeak, Cipla will provide comprehensive patient education and support programs. These will include instructions on dosing, self-administration, and the safe and informed use of the medication. These initiatives are intended to help patients confidently manage their treatment under the guidance of their healthcare providers. This approach reflects Cipla's ongoing commitment to providing evidence-based information and responsible care, empowering individuals to proactively manage their health and adopt sustainable wellness practices.
